SuperworthAmphastar Pharmaceuticals AMPH
- Market cap
- $1.1B
- PE
- 14.8×
- 10y median 20.6×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.5×
- EV/EBIT
- 12.2×
- Revenue, 12 months
- $730M
- +1% on a year ago
- Net margin
- 10.8%
- Free cash flow yield
- 14.3%
Amphastar Pharmaceuticals trades at 14.8× trailing earnings, cheaper than 75% of the last ten years. Revenue was $730M over the last twelve months, up 1% on a year earlier with a 11% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $180.6M+50% | $178.1M+32% | $171.8M+23% | $182.4M+25% | $191.2M+6% | $186.5M+5% | $170.5M−1% | $174.4M−4% | $191.8M+0% | $183.1M−2% | $171.2M+0% | $183.9M+5% | |
| Cost of revenue | $72.2M+17% | $82M+28% | $81.7M+24% | $87.2M+20% | $89.3M+24% | $99.9M+22% | $85.3M+4% | $87.9M+1% | $93.2M+4% | $97.4M−2% | $100.8M+18% | $90.4M+3% |
| Gross profit | $108.4M+85% | $96.1M+35% | $90.1M+22% | $95.2M+31% | $101.9M−6% | $86.6M−10% | $85.3M−5% | $86.5M−9% | $98.6M−3% | $85.7M−1% | $70.3M−18% | $93.5M+8% |
| R&D | $16.7M−10% | $20.4M+19% | $17M−14% | $17.7M+5% | $21.1M+27% | $18.1M−11% | $20.1M+18% | $20.1M+14% | $22.4M+6% | $23.3M+29% | $26.7M+33% | $22.2M+10% |
| SG&A | $19.1M+14% | $21.7M+35% | $25M+22% | $22.3M+17% | $23.8M+25% | $23.4M+8% | $27.9M+11% | $24.2M+9% | $51M+114% | $26.8M+15% | $30M+8% | $31.6M+30% |
| $72.7M+213% | $54M+43% | $48M+44% | $55.2M+50% | $57M−22% | $45.1M−16% | $37.3M−22% | $42.2M−24% | $25.3M−56% | $35.6M−21% | $13.6M−64% | $39.7M−6% | |
| Interest expense | $13.7M+2321% | $9.5M+1691% | $8.6M+2064% | $8.6M+139% | $6.7M−51% | $6.4M−32% | $6.3M−27% | $6.3M−27% | $6.3M−6% | $6.6M+3% | $6.6M+4% | $6.7M+6% |
| Pre-tax income | $63.6M+182% | $41.3M+0% | $47.9M+43% | $50.2M+53% | $47.7M−25% | $44M+6% | $30.9M−36% | $39.3M−22% | $21.5M−55% | $31.9M−27% | $10.1M−67% | $38.5M−2% |
| $14M+114% | $4.7M−36% | $4.1M−39% | $12.3M+93% | $7.3M−48% | $6M+28% | $5.6M+35% | $8.3M−32% | $4.2M−43% | $7.5M+25% | $3.6M−35% | $8.2M−1% | |
| Net income | $49.2M+210% | $36.2M+7% | $43.2M+66% | $37.9M+45% | $40.4M−18% | $38M+5% | $25.3M−41% | $31M−18% | $17.4M−57% | $24.4M−36% | $6.4M−75% | $30.3M−2% |
| $0.91+203% | $0.68+3% | $0.81+62% | $0.73+49% | $0.78−14% | $0.74+9% | $0.51−37% | $0.64−12% | $0.37−53% | $0.52−30% | $0.14−73% | $0.67+5% | |
| 53.9M+2% | 53M+3% | 53M+2% | 52M−2% | 51.9M−4% | 51.3M−3% | 49.9M−6% | 48.1M−8% | 47.7M−8% | 47.2M−8% | 46.5M−7% | 44.2M−8% |
Revenue: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY13: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY13: 6 months less the 3 months printed beside them.
R&D: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
SG&A: Q1 FY13: 6 months less the 3 months printed beside them.
Operating income: Q1 FY13: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY13: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Income tax: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Net income: Q1 FY14: 6 months less the 3 months printed beside them.
EPS, diluted: 10 periods, Q1 FY13 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY13: share-days: the 6-month average less the second quarter's. 7 periods, Q4 FY13 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY20: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Amphastar Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.6× | 1.9× | +6% | 2.0% | |
| ANABAnaptysbio | $1.5B | 10.7× | 100.0× | n/m | n/m | n/m | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| PAHCPhibro Animal Health | $1.6B | 15.9× | 21.5× | 1.0× | +17% | 6.6% | |
| ANIPANI Pharmaceuticals | $1.7B | 15.4× | 60.6× | 1.7× | +31% | 11.1% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| Peer median | $1B | 10.8× | 17.0× | 1.6× | +26% | 22.2% |
More on Amphastar Pharmaceuticals
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #6of 44Large drugmakers with the highest free cash flow yield
- #6of 17Large drugmakers cheapest against their own PE history
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .